Albuminar-20 Market Report 2026

Albuminar-20 Market Overview

• The Albuminar-20 market growth in the historic period has been driven by established role of albumin in volume expansion, growth of critical care admissions • Market expansion is supported by growth in icu admissions, expansion of trauma care centers • Growth Driver: Increasing Prevalence Of Chronic Diseases Fueling The Growth Of The Market Due To Rising Need For Long-Term Disease Management And Plasma Volume Support • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Albuminar-20 Market?

Albuminar-20 is a sterile, 20% human serum albumin solution used as a plasma volume expander and for other therapeutic purposes. It works by maintaining oncotic pressure, helping to restore and stabilize blood volume in conditions like hypovolemia, burns, or hypoalbuminemia. Albuminar-20 is derived from pooled human plasma, processed to reduce the risk of infectious agents, and primarily used in critical care settings. The main formulations in the albuminar-20 market are human serum albumin, recombinant albumin, and bovine serum albumin. Human serum albumin (HSA) is a protein found in human blood plasma that plays a critical role in maintaining oncotic pressure (the pressure that helps keep fluid within the blood vessels) and transporting substances such as hormones, fatty acids, and drugs. The various indications include shock treatment, burns, and hypoalbuminemia, and several distribution channels including hospital and clinics, and retail and specialty pharmacies. The different end users encompass hospitals and clinics, pharmaceutical and biotechnology industry, and research institutes.

What Is The Albuminar-20 Market Growth Forecast?

The growth in the forecast period can be attributed to growth in icu admissions, expansion of trauma care centers, increasing aging population, demand for stable plasma derivatives, improved plasma fractionation capacity. Major trends in the forecast period include sustained demand for high concentration albumin solutions, growing use in critical care and shock management, increased application in burn and trauma care, preference for plasma derived volume expanders, expansion of intensive care infrastructure.

Global Albuminar-20 Market Segmentation

1) By Formulation: Human Serum Albumin, Recombinant Albumin, Bovine Serum Albumin 2) By Indication: Shock Treatment, Burns, Hypoalbuminemia 3) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies 4) By End User: Hospitals And Clinics, Pharmaceutical And Biotechnology Industry, Research Institutes

What Are The Drivers Of The Albuminar-20 Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the albuminar-20 market going forward. Chronic diseases are long-lasting health conditions that usually progress slowly over time, such as diabetes, heart disease, and arthritis, and often require ongoing medical attention and lifestyle management to control symptoms and prevent complications. Chronic diseases are increasing largely due to unhealthy lifestyles, including poor diet, physical inactivity, and smoking, which raise the risk of conditions such as diabetes, heart disease, and obesity. Albuminar-20 supports chronic disease management by restoring plasma volume and improving fluid balance in patients with conditions such as liver cirrhosis, kidney disorders, and heart failure. It helps reduce complications linked to hypoalbuminemia, enhancing treatment stability and improving overall patient outcomes. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the albuminar-20 industry. The rising healthcare expenditure is expected to propel the growth of the albuminar-20 market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances albuminar-20 adoption by increasing access to advanced treatment options, ensuring better availability of essential plasma-derived therapies in hospitals and specialty care settings. It enables healthcare systems to invest in improved patient management for conditions requiring albumin therapy, leading to better clinical outcomes and greater treatment efficiency. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the albuminar-20 industry. The increase in surgical procedures is expected to propel the growth of the albuminar-20 market going forward. Surgical procedures are medical operations performed to diagnose, treat, or manage diseases, injuries, or other health conditions through manual or instrumental techniques. The rise in surgical procedures is largely driven by an aging population, leading to a greater need for surgeries such as joint replacements and cardiovascular operations. Albuminar-20 aids surgical procedures by supporting effective fluid resuscitation, making it essential for managing blood loss and maintaining hemodynamic stability during operations. It reduces perioperative complications by restoring plasma volume quickly and efficiently, improving overall surgical outcomes and patient recovery. For instance, in May 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, there were 778,500 patients were admitted for surgery from public hospital elective surgery waiting lists in 2023-24, a 5.8% increase compared with 2022-23. Therefore, an increase in surgical procedures will drive the growth of the albuminar-20 industry.

Key Players In The Global Albuminar-20 Market

Major companies operating in the albuminar-20 market are Grifols SA

Regional Insights

North America was the largest region in the albuminar-20 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Albuminar-20 Market?

The albuminar-20 market consists of sales of human serum albumin solutions and protein replacement or plasma volume expansion. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Albuminar-20 Market Report 2026?

The albuminar-20 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the albuminar-20 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.